<DOC>
	<DOCNO>NCT02068625</DOCNO>
	<brief_summary>This randomise , double-blind , placebo-controlled clinical trial investigates neuroprotective effect rasagiline patient suffer retinal detachment affect central vision . Based result study mice suffer retinal degeneration , investigator hypothesize rasagiline delay neurodegeneration retina improve visual acuity outcomes retinal detachment surgery . Rasagiline second-generation propargylamine neuroprotective property modulate caspase-dependent pathway program cell death .</brief_summary>
	<brief_title>Rasagiline ( Azilect ) - Neuroprotection Macula-off Retinal Detachment</brief_title>
	<detailed_description>Background In previous experimental study neuroprotection rasagiline show rds-mice , model slow retinal degeneration . It known experiment rasagiline specifically delays apoptosis , also modify inflammation autophagy . The bioavailability drug central nervous system high , base literature sufficient retina . In retinal detachment out layer neurosensory retina deprive nutrient degeneration photoreceptors occurs fast . This particularly relevant macular area retina density photoreceptors high , visual acuity recovery significantly limit photoreceptor loss . Objective To assess neuroprotective effect oral rasagiline ( 1mg daily 7 day ) administer perioperatively patient undergo surgical retinal detachment repair central vision involve retinal detachment . Methods In clinical trial , patient suffer retinal detachment affect fovea get randomly assign perioperative oral treatment either rasagiline ( 1mg ) placebo daily 7 day . Pharmacologic treatment initiate time hospital admission , usually day surgery . The main outcome study visual acuity six month surgical retinal detachment repair . Structural difference neurosensory retina group analyse optical coherence tomography , non-invasive imaging method retinal pathology .</detailed_description>
	<mesh_term>Retinal Detachment</mesh_term>
	<mesh_term>Dissociative Disorders</mesh_term>
	<mesh_term>Rasagiline</mesh_term>
	<criteria>Rhegmatogenous retinal detachment Central vision affect less 72 hour Pseudophakic Age 18 Not participate clinical trial Willing attend followup visit Written inform consent Exclusion Criteria Phakic Narrow angle glaucoma Previous intraocular surgery cataract operation Retinal disease Concurrent treatment MAO inhibitor Pregnancy Malignant arterial hypertension Liver kidney failure Lifethreatening malignant disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>retinal detachment</keyword>
	<keyword>rasagiline</keyword>
	<keyword>optical coherence tomography</keyword>
	<keyword>visual acuity</keyword>
	<keyword>neuroprotection</keyword>
	<keyword>azilect</keyword>
</DOC>